National Drug Policy (Second Edition) - Ghana: 6.0 RATIONAL DRUG USE: 6.3 Policy Statement: 6.3.8 Pharmacovigilance

Home page | Help | Clear

English | French

Full TOC

Expand Document

Expand Chapter

Preferences

Printable HTML version

Export document as HTML file Help


National Drug Policy (Second Edition) - Ghana (GNDP; 2004; 37 pages)
	PREFACE
	ACKNOWLEDGEMENT
	LIST OF ACRONYMS
	INTRODUCTION
	GOAL
	OBJECTIVES
	SITUATIONAL ANALYSIS
	1.0 DRUG SELECTION
		1.1 Preamble
		1.2 Objective
		1.3 Policy Statement
			1.3.1 Essential Drugs
	2.0 DRUG PROCUREMENT, STORAGE AND DISTRIBUTION
		2.1 Preamble
		2.2 Objective
		2.3 Policy Statement
			2.3.1. Procurement
			2.3.2 Storage
			2.3.3 Distribution
	3.0 DRUG FINANCING
		3.1 Preamble
		3.2 Objective
		3.3 Policy Statement
	4.0 QUALITY ASSURANCE
		4.1 Preamble
		4.2 Objective
		4.3 Policy statement
			4.3.1 Quality of Drugs.
			4.3.2 Drug Registration
			4.3.3 Quality of service
			4.3.4 Drug Advertisement and Promotion
	5.0 LOCAL MANUFACTURE OF PHARMACEUTICAL AND TRADITIONAL MEDICINAL PRODUCTS
		5.1 Preamble
		5.2 Objective
		5.3 Policy statement
	6.0 RATIONAL DRUG USE
		6.1 Preamble
		6.2 Objective
		6.3 Policy Statement
			6.3.1 Education and Training
			6.3.2 Drug Information
			6.3.3 Prescribing
			6.3.4 Dispensing
			6.3.5 Patient Compliance and Self-Medication
			6.3.6 Drug and Therapeutics Committees
			6.3.7 Disposal of expired drugs.
			6.3.8 Pharmacovigilance
	7.0 GLOBAL TRADE AND PHARMACEUTICALS
		7.1 Preamble
		7.2 Objective
		7.3 Policy statement
	8.0 EMERGING DISEASES AND PHARMACEUTICALS
		8.1 Preamble
		8.2 Objective
		8.3 Policy statement
	9.0 HUMAN RESOURCE DEVELOPMENT FOR DRUG MANAGEMENT
		9.1 Preamble
		9.2 Objectives
		9.3 Policy statement
	10.0 TRADITIONAL MEDICINAL PRODUCTS
		10.1 Preamble
		10.2 Objective
		10.3 Policy Statement
	11.0 RESEARCH AND DEVELOPMENT
		11.1 Preamble
		11.2 Objective
		11.3 Policy statement
	12.0 NATIONAL DRUG POLICY IMPLEMENTATION
		12.1 Preamble
		12.2 Objective
		12.3 Policy statement
			12.3.1 Operationalisation of Policy
			12.3.2 Monitoring and evaluation
	ANNEX A: DEFINITIONS
	ANNEX B: RELEVANT REGULATIONS ON PHARMACEUTICALS

6.3.8 Pharmacovigilance

6.3.8.1 The Ministry of Health shall support the setting up and maintenance of a National Centre for Pharmacovigilance (NCPv).

6.3.8.2 The NCPv shall be responsible for the regular collection of spontaneous reports from health care practitioners and the general public on adverse drug reactions (ADRs) occurring nationwide.

6.3.8.3 The NCPv shall be responsible for the identification of risk factors for, and mechanisms underlying, ADRs occurring in the country.

6.3.8.4 The NCPv shall continually process and disseminate information generated on ADRs to health care personnel, drug manufacturers and the general public.

6.3.8.5 Health care practitioners and the general public shall be encouraged to report all adverse drug reactions to the NCP.

6.3.8.6 All reports to the NCPv shall be treated in strict confidence.

Please provide your feedback

English | French